NCT06850324View on ClinicalTrials.gov

Evaluate the Precision of ABL-101 Perfluorocarbon and Fluorine-19 MRI for the Mapping of Atherosclerotic Plaque Composition and Inflammation in Patients Undergoing Carotid Endarterectomy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Atherosclerotic Disease, CarotidCarotid Endarterectomy
Interventions
DRUG

ABL-101 is administered at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour).

The doses of ABL-101 is administered using an IV infusion pump in the arm at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour). Patients will undergo a 1 hour-imaging with 19F MRI, 16h-36h after end of PFC infusion.

Trial Locations (1)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors
lead

Ruud van Heeswijk

OTHER